← Back to Clinical Trials
Recruiting NCT05801861

NCT05801861 Modulating Goal-directed Navigation Using Noninvasive Brain Stimulation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05801861
Status Recruiting
Phase
Sponsor Rutgers, The State University of New Jersey
Condition Spatial Navigation
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2023-03-24
Primary Completion 2026-08-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 55 Years
Study Type INTERVENTIONAL
Interventions
Active 10-Hz TMS to the parietal cortexActive single pulse TMS to the parietal cortexSham 10-Hz TMS to the right parietal cortex

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2023-03-24 with a primary completion date of 2026-08-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Our specific aim is to examine the effects of TMS on spatial processing during goal-directed navigation. In these experiments the investigators will utilize a scalp-recorded brain oscillation called right posterior theta that is believed to index the sensitivity of the parahippocampal cortex to spatial context. Here the investigators will asked whether this electrophysiological signal can be modulated up or down using TMS while participants engage in virtual navigation tasks, and if so, whether it would affect the spatial encoding of rewards and subsequent choices during task performance.

Eligibility Criteria

Inclusion Criteria: 1. Be between the ages of 18 and 55 years old. 2. Not received substance abuse treatment within the previous 30 days. 3. Be in stable mental and physical health. 4. If female, test non-pregnant. 5. No evidence of focal or diffuse brain lesion on MRI. 6. Be willing to provide informed consent. 7. Be able to comply with protocol requirements and likely to complete all study procedures. Exclusion Criteria: 1. Contraindication to MRI (e.g., presence of metal in the skull, orbits or intracranial cavity, claustrophobia). 2. Contraindication to rTMS (history of neurological disorder or seizure, increased intracranial pressure, brain surgery, or head trauma with loss of consciousness for \> 15 minutes, implanted electronic device, metal in the head, or pregnancy). 3. History of autoimmune, endocrine, viral, or vascular disorder affecting the brain. 4. History or MRI evidence of neurological disorder that would lead to local or diffuse brain lesions or significant physical impairment. 5. Life time history of mental disorders such as: Bipolar Affective disorder (BPAD), Schizophrenia, Post-traumatic Stress disorder (PTSD) or Dementia or Major Depression. uninterruptable central nervous system medication.

Contact & Investigator

Central Contact

Travis E Baker, PhD

✉ travis.e.baker@rutgers.edu

📞 973-353-5485

Principal Investigator

Travis E Baker

PRINCIPAL INVESTIGATOR

Rutgers University

Frequently Asked Questions

Who can join the NCT05801861 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Spatial Navigation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05801861 currently recruiting?

Yes, NCT05801861 is actively recruiting participants. Contact the research team at travis.e.baker@rutgers.edu for enrollment information.

Where is the NCT05801861 trial being conducted?

This trial is being conducted at Newark, United States.

Who is sponsoring the NCT05801861 clinical trial?

NCT05801861 is sponsored by Rutgers, The State University of New Jersey. The principal investigator is Travis E Baker at Rutgers University. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology